인쇄하기
취소

Kolon TissueGene starts Phase III clinical trial for ‘Invossa’

Published: 2018-07-11 15:36:58
Updated: 2018-07-11 15:39:24

Kolon TissueGene(CEO Bum-Seop Lee & Woo-Seok Lee) announced on the 6th that they acquired the Chemistry, Manufacturing and Controls(CMC) from the U.S. FDA and would start a Phase III clinical trial in the U.S.

Kolon TissueGene acquired approval of the Phase III clinical trial on May 2015 and has taken a process of getting the CMC by following standards suggested by the U.S. FDA. As getting the...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.